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ABSTRACT
Radioimmunotherapy (RIT) potentially is an attractive treatment for radiosensitive early-stage solid tu-
mors and as an adjuvant to cytoreductive surgery. Topical administration of RIT may improve the effi-
cacy because higher local concentrations are achieved. We reviewed the results of locally applied radi-
olabeled monoclonal antibodies for the treatment of solid tumors. Intracavitary RIT in patients with ovarian
cancer and glioma showed improved targeting after local administration, as compared to the intravenous
administration. In addition, various studies showed the feasibility of locally applied RIT in these patients.
In studies that included patients with small-volume disease, adjuvant RIT in ovarian cancer and glioma
showed to be at least as effective as standard therapy. The information about RIT for peritoneal carci-
nomatosis of colorectal origin is scarce, while results from preclinical data are promising. RIT may be
applied for other, relatively unexplored indications. Studies on the application of radiolabeled antibod-
ies in early urothelial cell cancer have been performed, showing that intracavitary RIT may hold a promise.
Moreover, in patients with malignant pleural mesothelioma or malignant pleural effusion, RIT may play
a role in the palliative treatment. Intracavitary RIT limits toxicity and improves tumor targeting. RIT is
more effective in patients with small-volume disease of solid cancers. RIT may have potential for pallia-
tion in patients with malignant pleural mesothelioma or malignant pleural effusion. The future of RIT
may, therefore, not only be in the inclusion in contemporary multimodality treatment, but also in the ex-
pansion to palliative treatment.
Key words: radioimmunotherapy, intracavitary, ovarian cancer, glioma, colorectal cancer, urothelial cell
cancer
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INTRODUCTION
Biologicals play an increasingly important role
in the treatment of cancer. Monoclonal antibod-
ies (mAbs) against CD20 are standard therapy
in non-Hodgkin’s lymphoma (NHL), anti-vas-
cular endothelial growth factor (VEGF) anti-
bodies are used to treat colon and lung carci-
noma and anti-HER2 antibodies play a role in
breast cancer treatment. mAbs can also be used
to direct anticancer drugs to tumor cells. Drugs,
toxins, or radionuclides can be conjugated to
mAbs for selective delivery of these agents to
tumor tissues, thus sparing normal tissues in
contrast to conventional systemic anticancer
therapies 1,2
In radioimmunotherapy (RIT), mAbs are la-
beled with radionuclides to selectively irradiate
tumor cells. RIT has proven to be effective in
hematologic malignancies but is less effective in
solid cancers.3–5 Large solid tumors have a lim-
ited blood supply, rendering these tumors less ac-
cessible for therapeutic agents being delivered via
the blood. Impaired blood supply and concomi-
tant ischemia make tumor cells less radiosensi-
tive.6,7 In addition, solid tumors have a high in-
terstitial fluid pressure that limits the uptake and
penetration of antibodies.8 As a result, in large
tumors, the uptake of mAbs from the blood is rel-
atively low and heterogeneous, thus limiting the
efficacy of RIT. In small tumor lesions, the up-
take of mAbs is higher and the heterogeneity of
antibody uptake within the tumor can be over-
come by the penetration range of the radiation.
Therefore, RIT seems to be an attractive adjuvant
therapy in small-volume disease or microscopic
residual tumor deposits. RIT may also be ad-
ministered topically in order to reduce systemic
activity and enhance tumor targeting. In addition,
there are conditions that are particularly suitable
for RIT owing to tumor localization (i.e., the de-
velopment of cancer within a natural cavity) and
its concomitant pharmacologic advantages. In
both preclinical and clinical studies, the mAb lev-
els in intraperitoneally growing tumors were
found to be higher during the first 24 hours after
intraperitoneal administration, as compared to
systemic administration, thus favoring this route
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Figure 1. Most important forms of monoclonal antibodies used in clinical radioimmunotherapy. (A) Whole (murine) IgG (MW
150 kDa). Va, variable region; Co, constant region. (B) F(ab)2 fragment (MW 100 kDa). (C) Fab fragment (MW 50 kDa). (D)
Chimeric IgG (67% human). The constant regions of the murine antibody have been replaced by their human analogs. (E) Hu-
manized IgG (90%–95% human). (F) Fully human IgG. (G) Bispecific antibody. The antibody, with both arms originating from
two separate antibodies, is reactive with two distinct antigens. Copyright British Journal of Surgery Society Limited. Reprinted
by permission from MJ Koppe, et al. Radioimmunotherapy and colorectal cancer (ref 57).
of administration.9,10 In this paper, we reviewed
the results of locally applied radiolabeled mAbs
for the treatment of solid tumors.
RADIOIMMUNOTHERAPY
Antibodies
Since the development of the hybridoma tech-
nology, it is possible to generate antibodies specif-
ically directed against tumor-associated anti-
gens.11 Murine antibodies were the first clinically
applied antibodies. A major disadvantage was 
the production of human antimouse antibodies
(HAMAs) that could induce humoral immune
responses. In order to reduce immunogenicity, re-
combinant DNA techniques were applied to pro-
duce chimeric and humanized mAbs.12 In chime-
ric mAbs, the variable regions of heavy and light
chains are of murine origin, and these are then
fused with the constant regions of human origin
(Fig. 1). In humanized mAbs, only the Compli-
mentarity Determining Regions (CDR) of the
murine origin are grafted in a human antibody
framework.13,14 To improve in vivo targeting
properties, new antibody constructs have been
produced, using recombinant DNA techniques
(e.g., scFv, minibodies, diabodies, and so forth).
Radionuclides
The most commonly used radionuclides in RIT
are beta-emitters. Beta-particles are electrons that
are emitted from the nucleus of an unstable atom.
In RIT, iodine-131 (131I) and yttrium (90Y) are
the most commonly used beta-emitters. More re-
cently, rhenium-186 (186Re), copper-67 (67Cu),
and lutetium-177 (177Lu) have also been applied
(see Table 1) The differences in physical half-life,
the presence or absence of gamma rays, the en-
ergy, and consequently the range of the beta-par-
ticles in tissue are important with respect to the ra-
diation dose that can be delivered to the tumor. For
example, 90Y-labeled mAbs are theoretically not
suitable for the treatment of minimal or residual
disease with a diameter of only a few millimeters
or less, since 70% of the radiation energy will be
deposited outside small tumors (diameter 5 mm)
owing to the high energy of the -particles (mean,
0.9 MeV).15 For this application, the use of 177Lu-
labeled antibodies with medium-energy electron
emissions is better suited.16 Internalization of the
radiolabeled antibodies depends on various fac-
tors, including the antibody itself and the targeted
antigen. All antibodies eventually are internalized
by the target cell and subsequently catabolized.17
When internalized, the radiolabeled mAb is de-
graded in the lysosomes. In case of radioiodinated
mAbs, the radiolabeled metabolites are excreted
from the cell. Labeling of mAbs with radiometals,
such as 90Y, 177Lu, and 67Cu, is performed by first
linking chemical moieties that can complex the
metal ions to the antibody (chelators such as
DTPA, DOTA, or TETA). When catabolized, the
radioactive metabolites of mAbs labeled with ra-
diometals are trapped in the lysosomes, increasing
the retention of these radiolabels in the tumor.18,19
INTRAPERITONEAL RIT
The abdominal cavity is lined with mesothelial
cells that not only play a role in the sliding of the
peritoneal surfaces, but also play an active roll in
the immunologic response, inflammation, and
coagulation.20 Peritoneal clearance is regulated
via the peritoneum that behaves as a semiperme-
able membrane and the lymphatic lacunae un-
derlining diaphragmatic stomata. This clearing
process starts within minutes after contamination
of the peritoneal cavity.
Antibodies administered into the peritoneal
cavity cross the peritoneal lining mainly by dif-
fusion. The rate of diffusion depends on the vol-
ume of the instilled agent and the concomitant 
increase in fluid pressure.21,22 Moreover, anti-
bodies will be cleared via the diaphragmatic
stomata. For RIT of intraperitoneal lesions, the
intraperitoneal (i.p.) administration is advanta-
geous, as compared to the systemic administra-
tion, because higher concentrations of the anti-
body can be reached in the tumor.23 When mAbs
are administered into the peritoneal cavity, their
pharmacokinetics are similar to that of other
large-serum proteins. Apart from specific bind-
ing to i.p. tumors, there is transportation to the
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Table 1. Radionuclides
Beta Gamma
Half- energy energy Range
Radionuclide life (KeV) (KeV) ()
131I 8 days 192 362 3 mm
90Y 64 hours 935 — 12 mm
188Re 17 hours 795 155 27 mm
177Lu 7 days 149 208 3 mm
67Cu 62 hours 141 185 2 mm
circulation and subsequent uptake in normal tis-
sues.24,25 However, in both preclinical and in
clinical studies, the concentration of mAbs in the
tumor lesions is higher during the first 24 hours
after an i.p. administration while blood levels are
lower, as compared to a systemic administration.
In addition, not only the tumor uptake is in-
creased, but also the tumor:nontumor ratio. This
favors this route of administration for i.p. grow-
ing tumors.10,26
Ovarian Cancer
Ovarian cancer mostly originates from the sur-
face epithelium of the ovaries, and in most pa-
tients, metastases are confined to the peritoneal
cavity without further distant metastases.27 The
overall survival rate is 35%. The majority of pa-
tients presents with advanced disease at the time
of diagnosis. Radical debulking, in combination
with platinum- or taxol-based chemotherapy, is
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Table 2. Ovarian Cancer
Median Tumor-
No. of survival associated Stable Partial
Author patients (months) antigen Antibody disease Remission remission Nuclide Dose
Epenetos 24 MUC1 HMFG1-2, 5/24 4/24 131I 140 mCi
et al.34 AUA1,
H17E2
Nicholoson 25 n.r. MUC1 HMFG1 90Y 18 mCi/m2
et al.35
Epenetos 52 52 MUC1 HMFG1 21/54 90Y
et al.36
Verheijen 224 MUC1 HMFG1 90Y 18 mCi/m2
et al.37
Meredith 12 TAG-72 CC-49 3/12 1/12 177Lu 10–30 mCi/m2
et al.40
Rosenblum 58 TAG-72 B72.3 30 2/52 2/57 90Y 1–25 mCi
et al.41
Alvarez 27 TAG-72 CC-49 2 3/27 177Lu 10–50 mCi/m2
et al.42
Meredith 44 TAG-72 CC-49 4/44 4/44 177Lu 40–45 mCi/m2
et al.44
Alvarez 20 TAG-72 CC-49 5/20 11/20 2/20 90Y
et al.a
Crippa 16 GP38 MOv-18 5/16 131I 100 mCi
et al.46
Mahe 6 CA-125 OC-125 3 131I 120 mCi
et al.47
Grana 16 CEA/TAG- n.s. 5/16 1/16 90Y
et al.b 72/GP38
Riva 10 MUC1 HMFG1 3 131I 92 mCi
et al.c TAG-72 HMFG2
H17E2 B72.3
Jacobs 17 PCCA 4/17 188Re
et al.d
n.r., not reported; n.s., not significant.
aAlvarez RD, Huh WK, Khazaeli MB, et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal ra-
dioimmunotherapy for ovarian cancer. Clin Cancer Res 2002;8:2806.
bGrana C, Bartolomei M, Handkiewicz D, et al. Radioimmunotherapy in advanced ovarian cancer: Is there a role for pre-tar-
geting with (90)Y-biotin? Gynecol Oncol 2004;93:691.
cRiva P, Marangolo M, Lazzari S, et al. Locoregional immunotherapy of human ovarian cancer: Preliminary results. Int J Rad
Appl Instrum B 1989;16:659.
dJacobs AJ, Fer M, Su FM, et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally
in ovarian carcinoma: Toxicity and clinical response. Obstet Gynecol 1993;82:586.
the standard treatment, resulting in 50% local re-
currences and a median survival of 2 years.28,29
Ovarian cancer seems to be well suited for i.p.
administered adjuvant RIT.30 The disease has been
targeted by using antibodies directed against tumor-
associated antigens as the mucin-1 (MUC1) anti-
gen, CA-125, TAG-72, and gp38 (see Table 2).
As mentioned above, several preclinical and
clinical studies demonstrated that an i.p. admin-
istration of RIT resulted in a higher uptake of ra-
diolabeled antibodies in tumor, as compared to
systemic route administration.10,26,31,32
MUC-1
MUC-1 is expressed on glandular epithelium 
in the majority of adenocarcinomas, including
breast, ovary, and pancreas, where it is both over-
expressed as well as aberrantly glycosylated.33
One of the first RIT trials in patients with ovar-
ian cancer was carried out by Epenetos et al.,
treating 24 patients with stage III ovarian cancer
in an adjuvant setting to cytoreductive surgery
and platinum-based chemotherapy. In this study,
131I-labeled anti-MUC1 mAbs, HMFG1-2, AUA
1, and H17E2, were used.34 The best response
was found in the 16 patients with minimal or
small-volume (2 cm diameter) disease. No re-
sponse was seen in the 8 patients with large-
volume disease (2 cm diameter) who all died
of recurrent disease within 9 months. In another
trial, the efficacy of adjuvant 90Y-labeled
HMFG1 following surgery and chemotherapy
was compared to a historic control group that was
treated with surgery and chemotherapy alone.
Five (5)-year survival in the RIT group was 80%,
as compared to 55% in the control group.35 Later,
these investigators reported that after 12 years of
follow-up, the median survival of a group with
complete remission following surgery, chemo-
therapy, and adjuvant 90Y-HMFG1 had not yet
been reached. These results were better than the
results in a historic control group that had a me-
dian survival of 42% survival after 5 years of fol-
low-up.36 Based on the encouraging results of
these phase I/II studies, a phase III open-label,
randomized, multicenter phase III trial was un-
dertaken. This study included patients to be
treated with 90Y-HMFG1 RIT (maximum dose,
25 mCi; N  224) and compared them to con-
ventionally treated patients (N  223).37 Patients
were eligible after a complete clinical response
to platinum-based chemotherapy following sur-
gical cytoreduction. Intraperitoneally adminis-
tered RIT was applied after a confirmed mac-
roscopically negative laparoscopy. This study
failed to show a benefit in overall survival or a
prolonged disease-free survival after RIT. Al-
though peritoneal recurrence was significantly
delayed in the RIT group, extraperitoneal metas-
tases, mainly located in the para-aortic lymph
nodes, were found more frequently than in the
control group (49% versus 14%).38
TAG-72
TAG-72 is a mucin-like antigen that is heteroge-
neously expressed in virtually all ovarian cancers.
The pharmacology, metabolism, and tissue dis-
tribution of 90Y-labeled anti-TAG-72 B72.3 was
investigated in 9 patients with ovarian cancer.39
Following this report, Meredith et al.40 and
Rosenblum et al.41 performed i.p. RIT studies in
patients with chemotherapy-resistant or refrac-
tory ovarian cancer limited to the peritoneal cav-
ity. Rosenblum et al. included 58 patients treated
with 90Y-labeled B72.3, 1–25 mCi, resulting in 2
complete remissions and 30 patients with stable
disease with a median of 6 months (range, 4–24).
In a study using 177Lu-labeled CC49, a second-
generation anti-TAG-72 antibody with a higher
affinity for TAG-72 than the B72.3 antibody
(dose, 10–50 mCi/m2), Alvarez et al. included 27
patients. Fourteen (14) of these patients with
small (1 cm) or microscopic disease were sta-
ble for 6–35 months, whereas in patients with
measurable disease (1 mm), only 1 patient
showed a partial response. The other patients
showed progression within 3 months.42 Meredith
et al. published a report including 12 patients
treated with 177Lu-labeled CC49, 10–30
mCi/m2.40 This resulted in complete remission in
3 patients and stable disease in 1. Complete re-
sponses were only found in patients with micro-
scopic disease. Following the report by Roselli et
al.,43 who showed that interferon (IFN) enhances
the expression of TAG-72, Meredith et al. sub-
sequently tested the feasibility and efficacy of a
combination of subcutaneous (s.c.) injections of
IFN, i.p. paclitaxel (100 mg/m2), and RIT con-
sisting of 40–45 mCi/m2 177Lu-labeled CC49.
This study included 44 patients with ovarian can-
cer, 27 of whom had only microscopic disease or
disease not measurable on computed tomography
(CT).44 Four (4) of 17 patients with macroscopic
disease on CT showed a partial response (de-
crease of 50% diameter), whereas 4 of 27 pa-
tients with microscopic disease showed progres-
sion-free time intervals of more than 18 months.
Subsequently, the same research group treated 20
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patients with persistent or recurrent ovarian cancer
after conventional cytoreductive surgery and che-
motherapy, with a combination of RIT using 90Y-
labeled CC49 and a single i.p. administered dose
of paclitaxel (100 mg/m2) and IFN. In 3 of 11 pa-
tients with nonmeasurable disease, disease-free sur-
vival was more than 18 months. The researchers
concluded that this combination of treatments was
well tolerated and showed antitumor activity.
gp38
MOv18 is an antibody directed against the folate
receptor gp38, which is expressed at high levels
in 90% of serous ovarian carcinomas. The ex-
pression level on other epithelial tissues is low.45
The murine MOv18 mAb is highly immunogenic,
inducing human antimouse antibodies (HAMA)
in most patients. MOv18 targeting of ovarian can-
cer was investigated by van Zanten-Przybysz et
al.26 by comparing the i.p. administration to the
intravenous (i.v.) injection. Ex vivo measured tu-
mor uptake after i.p. administration was 3.4%–
12.3%, whereas this was 3.6%–5.4% after the i.v.
administration.32 In addition, van Zanten-Przy-
bysz et al. determined the pharmacokinetics and
tumor accumulation of both i.v. and i.p. admin-
istered cMOv18 in the same patient in a dual-la-
bel 125/131I-study in 15 patients. They showed a
tumor uptake of 4.9% and 2.4% injected dose per
kilogram (ID/kg) after the i.v. and i.p adminis-
tration after 2 days, respectively. After 6 days,
there was no difference in tumor uptake between
the routes of administration (3.8% and 3.9%ID/
kg for i.v. and i.p). Moreover, the mean AUC for
the blood-activity versus time curve was 3.5
times higher after the i.v injection at 2 days and
2.1 times higher at 6 days, as compared to the i.p
injection. The researchers, therefore, concluded
that the i.p. route could be advantageous owing
to the significantly lower bone marrow toxicity
as a result of lower blood levels of the radiola-
beled antibody when administered i.p.26
Crippa et al. tested the efficacy of i.p. admin-
istered RIT, using 131I-MOv18 (mean dose, 100
mCi) in 16 patients with minimal or small-vol-
ume ovarian cancer.46 Clinical follow-up and/or
third-look evaluation performed 90 days after the
administration of RIT showed a complete re-
sponse in 5, stable disease in 6, and progressive
disease in 5 patients. Of the 5 patients that
showed a complete response, 1 patient remained
disease free after a follow-up of 34 months,
whereas the remaining 4 patients relapsed after a
mean period of 10.5 months.
CA-125
Mahe et al. performed a phase I study comprising
of i.p. administered 120 mCi of the 131I-labeled
anti-CA-125 antibody OC125 to 6 patients with
residual macroscopic (5 mm) or microscopic
disease, resulting in stable disease in 2 patients.47
In addition, there was HAMA formation in all 6
patients. The reported lack of efficacy might be
owing to the nature of CA-125, being a antigen
that is shed from the cell membrane.48,49
In conclusion, the data available on the use of
adjuvant i.p. RIT in patients with ovarian cancer
show improved targeting after the i.p. adminis-
tration, as compared to the i.v. administration.
Despite the lack of survival benefit, the phase III
study with 90Y-HMFG1 showed an improved lo-
cal control of i.p. disease in patients treated with
RIT.
Colorectal Cancer
Colorectal cancer (CRC) may spread intraperi-
toneally, causing peritoneal carcinomatosis (PC).
In 25% of the patients with recurrent CRC, this
is the only site of metastasis.50 If untreated, pa-
tients suffering from PC have a median survival
of only 6 months.51 Today’s gold standard for the
treatment of PC is cytoreductive surgery, fol-
lowed by heated i.p. chemotherapy or HIPEC.50
This highly specialized, extensive treatment is as-
sociated with a high morbidity (14%–55%) and
high mortality (19%).50 Although the results of
this treatment are promising, the median survival
is 13–34 months52,53 and the 5-year survival rate
is 19%–27%.54,55 Owing to the high complica-
tion rates, there is a need for new treatment mo-
dalities.
RIT for CRC has been under clinical investi-
gation since 1992, mainly with anti-carcinoem-
bryonic antigen (CEA) antibodies.56 The results
of RIT in CRC were recently reviewed by our
group.57 So far, only one trial gave the results of
i.p. administered RIT in patients with advanced
CRC. Patients with local as well as regional and
systemic spread were included.58 Thirty-one (31)
patients with large peritoneal metastases were
treated. Patients received 5 cycles of i.p. admin-
istered 131I-labeled anti-CEA/TAG-72/MUC-1.
This was done either as monotherapy (one anti-
body) or in combination with multiple antibod-
ies. The average activity dose per cycle was 98
mCi. The researchers reported a median survival
of 41 months, complete remission lasting 23
months in 10 patients, stable disease that lasted
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for 12 months in 8 patients, and a partial remis-
sion in 10 patients.
Preclinical studies in mice with colon cancer
xenografts were performed by Keenan et al. as
early as 1984, suggesting RIT might be success-
ful for the treatment of colon cancer in humans.59
The preclinical as well as the clinical investiga-
tions of this group focussed on the i.v. route of
administration, despite a more efficient tumor tar-
geting in patients with PC after a i.p. adminis-
tration than after an i.v. administration, as shown
in a dual-label study of concomitant i.v.- and i.p.-
administered 131I-labeled B72.3.10
In nude mice with i.p. growing human colon
carcinoma, the i.p. route of administration of ra-
diolabeled MN14, an anti-CEA antibody, showed
a higher tumor uptake during the first 48 hours
(58.5%  6.8%ID/g for i.p. vs. 34.9%  4.7%
ID/g for i.v.) after administration. Thereafter, the
uptake was similar.60 In addition, an increased
therapeutic efficacy of 177Lu-(median survival,
136 days) and 131I-labeled MN14 (median, 100
days) was reported, when compared to equitoxic
doses (8.33 MBq) of 90Y-(median, 82 days) and
186Re-labeled MN14 (median, 72 days) in this
model.61 The feasibility of i.p. RIT in an adju-
vant setting to cytoreductive surgery, leaving
only microscopic disease, was also investigated
by Koppe et al. The researchers used 177Lu-la-
beled MG1, a radiolabeled anti-CC531 (rat colon
carcinoma) antibody administered after cytore-
ductive surgery (CS). In this model, adjuvant RIT
resulted in a significantly improved survival of
rats treated with the combination of CS and RIT,
as compared to either CS or RIT alone.62 Despite
these favorable preclinical studies, there are no
clinical trials investigating the efficacy of RIT as
an adjuvant treatment to cytoreductive surgery
for peritoneal carcinomatosis of colorectal origin.
In conclusion, RIT is an effective treatment for
i.p. metastases and an effective adjuvant to cy-
toreductive surgery in preclinical studies. The
limited experience in phase I clinical trials war-
rants clinical studies.
RIT IN BRAIN TUMORS
An estimated 41,000 cases of primary central ner-
vous system (CNS) tumors occur annually in the
United States, 42% of which are glial tumors that
are, in most cases, malignant.63 Glioblastoma
multiforme, the most malignant form of CNS tu-
mors, offers patients a very poor overall survival
of only 3.3% after 2 years, despite the combina-
tion of surgery, radiotherapy, and chemother-
apy.64 More than 90% of all recurrences are ad-
jacent to the site of origin, indicating a failure of
local tumor control. Conventional radiotherapy
plays a primary role in brain cancer treatment.
However, its lack of tumor specificity is a sig-
nificant limitation of this form of therapy. Ow-
ing to its nonspecific nature, toxicity to normal
brain limits the radiation dose that can be deliv-
ered to tumor cells and compromises the quality
of life of the few longer term survivors. There are
three factors responsible for treatment failure: (1)
the delivery of therapeutic agents is limited by
the blood-brain barrier (BBB), despite the fact
that it is disrupted in regions of macroscopic tu-
mor65; (2) dysfunctional tumor vasculature, as is
the case in most solid tumors, leads to local hy-
poxia and a reduced responsiveness to chemo-
and radiotherapy in combination with an elevated
intratumoral interstitial pressure66–68; (3) inter-
and intratumoral cellular and genetic hetero-
geneity, leading to heterogeneous antigen ex-
pression.69,70
In general, adjuvant treatment consists of the
use of local radiation by means of stereotactic ra-
diotherapy or brachytherapy with implanted 125I
rods. However, these approaches did not show
additional effects on survival.71,72 Recent appli-
cations of combinations of chemotherapy (temo-
zolomide) with radiotherapy showed a survival
benefit. The majority of patients, however, died
within 1–2 years from progressive disease, un-
derlining the need for new treatment strategies.73
The BBB regulates the exchange of substances
between the vasculature and the CNS. This phys-
iologic barrier is composed of tight junctions be-
tween the capillary endothelial cells and is sup-
ported by a microenvironment of astrocytes,
pericytes, and microglial cells.74 This almost im-
penetrable barrier prohibits the delivery of po-
tentially effective therapeutic agents, thereby lim-
itating the treatment of CNS diseases. In the case
of malignant disease, the deterioration of the
BBB may occur, which may improve the delivery
of therapeutic agents to the CNS. Brain tumors can
cause a complete breakdown of the BBB, eventu-
ally leading to peritumoral, vasogenic edema.74
Imaging of CNS malignancies, using radiolabeled
antibodies, showed intratumoral accumulation fol-
lowing the i.v. administration, allowing for scinti-
graphic imaging. This indicates damage to the
BBB. However, in general, there is insufficient tar-
geting for therapeutic studies.75
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To overcome the problem of limited penetra-
tion, the locoregional application of therapeutic
agents in patients with malignant glioma has been
investigated.76 To investigate the application of
RIT, candidates for therapy, or tumor-associated
antigens (TAAs), needed to be identified.
Tenascin-c
In the majority of clinical RIT studies in glioma
patients, antitenascin mAbs were used. m81C6,
a murine IgG2b with affinity for tenascin-c (TN),
has been administrated through a s.c. implanted
reservoir connected to an intracavitary-placed
drain. TN is an extracellular matrix protein mod-
ulating cell-matrix interactions,77 which is over-
expressed in malignant glioma tissue, but not ex-
pressed in the normal brain. The distribution and
intensity of TN expression correlates well with
tumor neovasculature and shows evident expres-
sion in aggressive histotypes as well as in those
tumors with high proliferation indices.78–80 This
distribution of TN makes it a suitable target in
RIT in glioma (see Table 3).
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Table 3. Intra-Squamous Cell Carcinoma Radioimmunotherapy
Tumor- Median
No. of associated survival Stable Partial
Author patients Indication antigen Antibody (months) disease Remission remission Nuclide Dose
Bigner et al.81 42 GB/AA/AO TN 81C6 131I 100 mCi
Cokgor et al.83 42 GB/AA/AO TN 81C6 20 weeks 4/42 131I 20–180 mCi
Reardon 33 GB/AA/AO TN 81C6 79–85 weeks 0 n.r. n.r. 131I 120 mCi
et al.84
Reardon 43 GB/AA/AO TN 81C6 69 weeks 0 0 0 131I 120 mCi
et al.85
Reardon 47 GB/AA/AO TN ch81C6 89 weeks 131I 80–100 mCi
et al.86
Riva et al.88 10 GB TN BC-2/4 3/10 1/10 2/10 15 mCi
Riva et al.90 50 GB TN BC-2/4 20 months 11/50 3/50 6/50 131I
Riva et al.91 111 GB/AA/AO TN BC-2/4 19 months 10 1 9 131I 70 mCi
Riva et al.a 23 GB TN BC-2/4 16 months 5/23 3/23 3/23 131I 15–57 mCi
Riva et al.b 20 GB/AA TN BC-4 n.r. 0 0 0 90Y 5–30 mCi
Mamelak 19 GB/AA TN TM-601 27 weeks 131I 10 mCi
et al.c
Riva et al.b 17 GB 3/17 3/17
Pöpperl 24 GB/AA TN 12–87 7/24 131I/188Re 150–13 Mci
et al.d
Goetz et al.e 37 GB/AA TN 17 n.r. n.r. n.r. 131I/90Y
Paganelli 24 GB/AA TN BC-4 11/19 12/24 6/24 90Y 15–30 mCi
et al.93
Papanastassiou 7 Glioma NCAM ERIC-1 n.r. n.r. n.r. n.r. 131I
et al.f
n.r., not reported.
aRiva P, Arista A, Tison V, et al. Intralesional radioimmunotherapy of malignant gliomas: An effective treatment in recurrent
tumors. Cancer 1994;73:1076.
bRiva P, Franceschi G, Frattarelli M, et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific
monoclonal antibodies labeled with 90Y: A phase I study. Clin Cancer Res 1999;5:3275s.
cMamelak AN, Rosenfeld S, Bucholz R, et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in
adults with recurrent high-grade glioma. J Clin Oncol 2006;24:3644.
dPöpperl G, Gotz C, Rachinger W, et al. Serial O-(2-[(18)F]fluoroethyl)-L: -Tyrosine PET for monitoring the effects of intra-
cavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 2006;33:792.
eGoetz C, Rachinger W, Poepperl G, et al. Intralesional radioimmunotherapy in the treatment of malignant glioma: Clinical
and experimental findings. Acta Neurochir Suppl 2003;88:69.
fPapanastassiou V, Pizer BL, Coakham HB, et al. Treatment of recurrent and cystic malignant gliomas by a single intracavity
injection of 131I monoclonal antibody: Feasibility, pharmacokinetics and dosimetry. Br J Cancer 1993;67:144.
A series of phase I–III studies has been con-
ducted at Duke University. In the first phase I
study, 42 patients with recurrent glioma were in-
cluded and the maximal tolerable dose (MTD)
was assessed in a dose-escalation study after in-
tracavitary (into the surgically created cavity;
SCC) administration. This study showed that the
MTD was 100 mCi for intracavitary-adminis-
tered 131I-labeled 81C6, with neurotoxicity being
the dose-limiting factor.81 The results of this
study suggested that there was a potential 
survival benefit, as compared to patients treated
with stereotactic radiotherapy and high-dose
brachytherapy (a median survival of 60 weeks in
the present study, as compared to 41 and 46
weeks, respectively). In the second study, 42 pa-
tients with newly diagnosed glioma were in-
cluded in order to investigate dosimetry and dose-
response relationships.82,83 In these patients, the
MTD was 120 mCi, with neurotoxicity being the
dose-limiting factor. The median survival of
these patients was 79 weeks, as compared to 46
weeks of historic controls, when patients were
treated with surgery, chemotherapy, and radio-
therapy. Based on these encouraging results, a
phase II trial was performed in 33 patients with
newly diagnosed, previously untreated patients.
The median survival after treatment with 120
mCi of 131I-labeled 81C6 in this study was 79–85
weeks, depending on the pathologic type of
glioma (patients with astrocytic oligoden-
droglioma showed a better response than those
with glioblastoma multiforme).84 When 100 mCi
of radiolabeled antibody was administered to 43
patients with recurrent glioma, survival was still
69 weeks.85 The results of these trials warranted
a phase III trial, which is currently ongoing.
Recently, a human/mouse chimeric mAb, origi-
nating from 81C6, has been developed, showing
better tumor targeting in animal studies. The target-
ing capabilities of the antibody were subsequently
tested in a phase I study that included 47 patients
with recurrent disease.86 This chimeric antibody
showed a prolonged retention time within the SCC,
as compared to the antibody of murine origin. Ow-
ing to the enhanced circulatory half-life of the chi-
meric antibody, a MTD of 80 mCi was found, as
compared to 120 mCi found in previous studies
with the murine antibody. In this phase I dose-es-
calation study, the median survival was 87 weeks
for patients with newly diagnosed glioma and 65
weeks for those patients with recurrent disease.
Riva et al. used another anti-tenascin antibody
labeled with 131I, BC-2/4, initially injected directly
into the tumor.87 Thereafter, the antibody was, in
some patients repeatedly, administered into the
SCC in 23 patients with recurrent glioblastoma. In
their first report, no toxicity and an objective re-
sponse in 11 patients, in whom were 3 complete
remissions and a median survival of 16 months,
were reported.88 The follow-up study compared
the results of antibody administration in recurrent
and newly diagnosed patients.89 The reported to-
tal median survival was 20 months. When bulky
(median, 17 months) versus minimal disease (me-
dian, 26 months) were compared, the results sup-
ported the concept that RIT is most suitable in pa-
tients with small-volume disease. Later, combined
data of 111 patients that were included in phase I
and II studies showed a median survival of 20
months.90 The researchers concluded that the ap-
plication of RIT is most suitable in small-volume
disease. In a following phase I study,91 the re-
searchers switched to the application of an other
radionuclide, 90Y, in 20 patients and determined
the MTD to be 25 mCi with neurotoxicity as the
dose-limiting toxicity. No diffusion of the radio-
labeled antibody to normal tissue was reported.
However, this study failed to show clinical re-
sponses, presumably owing to the inclusion of pa-
tients with advanced disease.
Paganelli et al.92,93 investigated the use of the
pretargeting technique consisting of the biotinyl-
ated antitenascin MAb BC4, avidin and 90Y-bi-
otin, both i.v. administered as well as directly into
the SCC, following surgical debulking. In this pre-
targeting approach, the large IgG-avidin conjugate
was administered first, followed by a 90Y-labeled
biotin injection. These studies showed no hema-
tologic toxicity following the RIT when applied
into the SCC, as compared to almost all the other
studies that used mAbs, including the study where
pretargeting was used and administered i.v. This
latter study supports the local administration tech-
nique by showing a total body distribution of the
biotinylated mAb and fast blood clearance within
hours after the i.v. administration.
To summarize, the phase I–II studies from
Duke University on the use of adjuvant RIT af-
ter debulking surgery in patients with malignant
glioma indicate an improved survival, as com-
pared to historic control groups. In addition, there
was a reduction in treatment-related toxicity,
compared to stereotactic radiotherapy or brachy
therapy. This resulted in a phase III trial that is
currently ongoing. The results from Riva et al.,
despite the more heterogeneous group of patients,
support this conclusion.
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INTRAVESICAL RIT
Bladder cancer is the second most common can-
cer of the genito-urinary system, mainly occur-
ring in men. Two distinct types of urothelial can-
cer exist, the majority of which are superficial
and noninvasive. However, the remaining 20%
are solid, highly aggressive bladder cancers that
are invasive and metastasize in an early phase of
the disease.94 Cystectomy is the treatment of
choice for a tumor stage of T2–T4 (muscle inva-
sive), leaving local resection to CIS and T1 dis-
ease. In T1 urothelial carcinoma recurrence rates
are as high as 80% after resection.95 When in-
travesical chemotherapy is added to surgery, re-
currence rates are reduced by 50% at 2 years. Part
of the contemporary bladder-sparing treatment is
the use of immunotherapy by means of an in-
travesical Bacille Calmette-Guérin (BCG) instil-
lation, the results of which are comparable to
those achieved with chemotherapy.96 Since the
standard therapy in invasive bladder cancer is
radical cystectomy, the role of RIT is limited to
CIS and T1 disease.
Despite several preclinical experiments, reports
on the clinical use of radiolabeled antibodies in pa-
tients with bladder cancer are limited to investi-
gations on radioimmunoscintigraphy studies rather
than RIT (see Table 4). In these studies, antibod-
ies directed against the target antigen MUC-1 are
used. MUC-1 mucin is a high-molecular-weight
cell-surface glycoprotein that is found on normal
urothelium and that is both unregulated as well as
abnormally glycosylated in bladder cancer.97 One
of the first studies in 20 patients was performed
by Bamias et al., who intravesically administered
the 111In-labeled anti-MUC-1 antibody HMFG2.98
Autoradiography of the resected specimen showed
selective tumor targeting. Murray et al. used an in-
travesically administered 188Re-labeled C595 an-
tibody in 3 patients with transitional cell carci-
noma.99 In addition, this group investigated the
intravesical administration of 67Cu-labeled C595
in 16 patients with bladder cancer and studied the
systemic absorption of the radiolabeled anti-
body.100 The results of this study showed no de-
tectable activity above the background, meaning
there was no systemic radiolabel present after the
local application, while 80% of the tumors were
successfully visualized.
Malamitsi et al. investigated the intravesical
application of 99mTc-labeled MUC-1 antibody
HMFG1 in 14 patients and concluded that, de-
spite the excellent imaging of tumors, future at-
tempts to administer RIT using HMFG1 should
not be undertaken owing to a low and heteroge-
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Table 4. Intravesical Radioimmunoscintigraphy
Tumor-
No. of associated
Author patients Indication antigen Antibody Nuclide Targeting
Bamias et al.98 21 SUC MUC1 HMFG2 111In 	
Simms et al.a 21 SUC-T2-metastatic MUC1 C595 99mTc 16/20
invasive bladder
cancer
Murray et al.99 5 TCC MUC1 C595 188Re 4/5
Hughes et al.100 16 SUC-T2 MUC1 C595 67Cu 12/16
Malamitsi et al.101 15 SUC MUC1 HMFG1 99mTc/131I 
Chinol et al.b 12 TCC n.r. Avidin 99mTc 10/12
Syrigos c 6 SUC MUC1 HMFG1 131I 4/6
Kunkler et al.d 12 SUC MUC1 NCRC48 111In 	
n.r., not reported.
aSimms MS, Perkins AC, Price MR, et al. 99mTechnetium-C595 radioimmunoscintigraphy: A potential staging tool for blad-
der cancer. BJU Int 2001;88:686.
bChinol M, De CO, Trifiro G, et al. Localization of avidin in superficial bladder cancer: A potentially new approach for ra-
dionuclide therapy. Eur Urol 2003;44:556.
cSyrigos KN, Khawaja M, Krausz T, et al. Intravesical administration of radiolabelled tumour-associated monoclonal antibody
in bladder cancer. Acta Oncol 1999;38:379.
dKunkler RB, Bishop MC, Green DJ, et al. Targeting of bladder cancer with monoclonal antibody NCRC48—a possible ap-
proach for intravesical therapy. Br J Urol 1995;76:81.
neous uptake in the 6 patients with positive imag-
ing (0%–9% injected dose) caused by heteroge-
neous antigen expression.101
In conclusion, intravesically administered RIS
in bladder cancer may hold a promise for RIT,
using anti-MUC1 antibodies, in early urothelial
cell cancer owing to selective targeting and low
systemic concentrations of the targeting agent.
INTRATHORACIC RIT
The prognosis of patients with malignant pleural
mesothelioma (MPM) is poor. In general, median
survival is 6–16 months. The malignant form can
be classified in two categories: diffuse or local-
ized. Both are essentially insensitive to any treat-
ment.102 Different agents for intracavitary che-
motherapy to treat mesothelioma have been
utilized. The response rate varied between 15%
and 37%, without effect on survival, even when
used in combination with paclitaxel and doc-
etaxel. The clinical data regarding studies that
used intrathoracic chemotherapy adjuvant to sur-
gical debulking were disappointing.103,104 There-
fore, the intrathoracic application of chemother-
apeutic agents is mainly used to treat malignant
pleural effusion.105,106 Another obstacle for RIT
of mesothelioma is the low tumor antigen (meso-
thelin, tenascin-c) expression.107 Enhancing anti-
gen expression with proinflammatory cytokines,
however, do not improve survival after immuno-
therapy.108
Mesothelin is a 40-kD cell-surface glycosylated
phosphatidylinositol (GPI)-anchored glycopro-
tein, with functions in cell-to-cell adhesion ex-
pressed by normal mesothelial cells. It is highly
overexpressed in cancers as malignant mesothe-
lioma, pancreatic or ovarian carcinoma sarcomas,
and in some gastrointestinal or pulmonary carci-
nomas.109 In preclinical studies, Hassan et al. and
Fan et al. have used antimesothelin antibodies and
antibody fragments linked to exotoxins to treat
mesothelin-expressing tumors in nude mice. The
development of experimental metastases was in-
hibited, and even a complete regression of the tu-
mor was observed in some cases. 110,111
In conclusion, this antigen may be an attractive
target for the intrathoracic application of RIT, but
no clinical RIT studies have been performed. Cur-
rently, a clinical trial is being conducted, using a
chimeric mAb (MORAb-009) directed against a
cell-surface glycoprotein, GP-9, that is overex-
pressed in epithelial type cancers as mesothelioma,
ovarian, and pancreatic cancer.* GP-9 may, there-
fore, be a potentially suitable target for radiola-
beled MORAb-009 in future RIT of MPM.
Malignant pleural effusion (MPE)
MPE is thought to arise from tumor emboli de-
taching from visceral tumor nodules and concomi-
tant attachment to the parietal pleura. Also, direct
tumor invasion (in lung cancers, chest wall neo-
plasms, and breast carcinoma), hematogenous
spread to the parietal pleura, and lymphatic in-
volvement may be a mechanism for development
of MPE. The effusion is composed of extracellu-
lar matrix proteins, cytokines, and growth factors,
thereby promoting cell proliferation and inva-
sion.112 In women, the most common causes of
these effusions are breast and ovarian cancer,
whereas in men, these are lung cancer and malig-
nant pleural mesothelioma. Treatment of this spe-
cific entity can be done by either therapeutical pleur
aspiration (in case of a very short life expectancy),
talc pleurodesis, or indwelling catheters. MPM
with MPE is also an indication for intrapleural ther-
apy, as is the case with MPE arising from ovarian
cancer. Schmidt et al. described the successful in-
trapleural application of rituximab, an anti-CD20
mAb, in a patient with NHL who was free of symp-
toms for 8 months after this treatment.113 The re-
searchers described a case report regarding treat-
ment failure of repeated percutaneous drainage and
bilateral continuous chest tube drainage. This re-
sult may be promising, in particular when consid-
ering the possibilities of the effects of the applica-
tion of radiolabeled antibodies. This is the case with
90Y-labeled ibritumomab tiuxetan for the treatment
of NHL, where the RIC produces significantly bet-
ter responses than the mAb alone.114
Awaiting the results of the trial using MORAb-
009 in the case of MPM and the future develop-
ment of TAAs directed against MPM, there may
be a role for RIT in the treatment of MPM. In ad-
dition, RIT may play a role in the palliative treat-
ment in patients with MPE, regardless of the ori-
gin of the primary tumor.
DISCUSSION
The intracavitary application of radiolabeled an-
tibodies combines the advantage of high tumor
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*Source: Trial number: NCT00325494. www.clinicaltrials.
gov Accessed January 28, 2008.
doses and low systemic toxicity. Therefore,
higher doses of RIT can be applied than with sys-
temic administration.
Currently, RIT with radiolabeled anti-CD20
antibodies is an accepted treatment for patients
with NHL. For other indications, only a limited
number of clinical phase I/II and one phase III
RIT trials have been performed, using different
antibodies and radionuclides in patients with dif-
ferent types of cancer. The results various stud-
ies on the therapeutic efficacy and toxicity of RIT
in patients with ovarian cancer (90Y-HMFG-1,
177Lu-B72.3) and malignant glioma (131I-81C6)
indicate that the adjuvant application of RIT
within a confined area limits toxicity and im-
proves tumor targeting. In addition, RIT should
be applied as a treatment of patients with mini-
mal residual or microscopic disease of solid can-
cers in order to gain from its maximal potential.
For the treatment of ovarian cancer, the appli-
cation of RIT was studied in a randomized, phase
III trial. Unfortunately, the results of the latter
study showed no survival benefit. The lack of ef-
ficacy of adjuvant RIT in this trial could be ow-
ing to several factors. First, the selection of the
high-energy beta-emitter 90Y, with a maximum
tissue penetration of 12 mm, is not appropriate,
since most of the energy will be deposited out-
side small tumor deposits in small-volume or mi-
croscopic disease. Second, the protein dose was
augmented with 20 mg of unlabeled antibody to
a total of 25 mg 90Y-HMFG1, with the intent to
provoke a human antimouse antibody response.
This high antibody dose might have had a nega-
tive effect on the uptake of the radiolabel in the
tumor lesions owing to the saturation of MUC-1
epitopes on the tumor cells.115 In the future, how-
ever, optimizing this treatment, using nuclides
such as 177Lu that are more suitable for minimal
residual disease than 90Y in order to enhance the
antitumor effect, may result in survival benefit.
The same can be true for the treatment of peri-
toneal carcinomatosis of colorectal origin when
trials will be undertaken to treat this entity.
Progress has been made in the treatment of re-
current glioma by the application of RIT and this
treatment may, therefore, become an additional
adjuvant treatment modality in neuro-oncology.
CONCLUSIONS
In the case of superficial bladder cancer, promis-
ing results of preclinical and radioimmuno-
scintigraphy studies may precede phase I and II
trials. When therapeutic options are no longer
available, RIT may offer patients a chance of
minimally invasive palliation in patients with
MPM or MPE. The future of RIT may, therefore,
not only be in the inclusion in contemporary mul-
timodality treatment, but also in the expansion of
its indication to palliative treatment as a supple-
ment or even a substitution for present-day treat-
ments.
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